Novo Nordisk ® hlights first six months of 2021 Blue indicates developments in Q2 2021 Diabetes care: • Ozempic ® approved in China • Resubmission of semaglutide 2.0 mg in the US Obesity care: • Decision to initiate phase 3a development with 50 mg oral semaglutide in obesity • Approval of Wegovy ™, semaglutide 2.4 mg, in the US Other serious chronic disease: • Phase 3a development programmes initiated for treatment of NASH and Alzheimer’s Disease • Stem cell R&D licence agreement with Heartseed and acquisition of Prothena's ATTR amyloidosis programme Sales growth of 12% and Operating profit growth of 9%: • Sales in International Operations grew by 13% • Sales in North America Operations grew by 11% and in the US, 56% of sales came from products launched since 2015 Gross margin positively impacted by productivity gains in Product Supply Free cash flow of DKK 32.7 billion and DKK 21.9 billion returned to shareholders ncial outlook or expected growth. Note: Unless otherwise specified growth rates are at constant exchange rates and Drug Administration; EMA: European Medicines Agency; GHD: Growth Hormone Deficiency; HFpEF: Heart Failure with
Download PDF file